Axsome Therapeutics, Inc. (AXSM) Q1 2019 Earnings Results

Axovant Therapeutics Misses on EPS, Stock Up 0.87%

The earnings report showed a loss per share of $-0.32, which was expected but not compared to consensus. Despite the loss, the stock reacted positively, increasing by 0.87%. This suggests that investors may be encouraged by management's focus on future clinical developments, even in the absence of revenue figures.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.32	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a cautious optimism about their pipeline. They are committed to their research and development efforts despite the lack of revenue.

Management emphasized their focus on advancing clinical programs.

They highlighted ongoing research efforts and potential future milestones.

Axovant Therapeutics Misses on EPS, Stock Up 0.87%

Key numbers

Management commentary

Axsome Therapeutics, Inc.

More earnings this week

Axovant Therapeutics Misses on EPS, Stock Up 0.87%

Key numbers

Management commentary